GTHP
Guided Therapeutics, Inc.0.2500
-0.0200-7.41%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
20.90MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
10-K
FY2025 results
Guided Therapeutics posted FY2025 revenue of $767K from LuViva device sales and disposables to China, up sharply from $7K in 2024, with Q4 capturing $489K of previously deferred revenue after partner SMI breached its agreement. Gross profit hit $571K despite $75K inventory charges crimping margins; R&D fell 11% to $469K while G&A ballooned 78% to $2.3M on stock comp and salary hikes. Net loss widened to $3.3M amid debt conversions and $533K extinguishment losses, leaving $63K cash against $6M working capital deficit and $1.13M debentures in default. Q4 momentum built on China orders ($900K pipeline) and Turkey/Indonesia pilots, but liquidity strains persist. Auditors flag going concern doubts; Russia-Ukraine conflict risks commercialization there.
8-K
Warrant exchange wraps up
10-Q
Q3 FY2025 results
Guided Therapeutics posted Q3 sales of $60K from LuViva devices, up from zero y/y, driving gross profit of $35K while operating loss narrowed to $485K from $561K y/y. QTD revenue totaled $177K, +29x y/y, but YTD operating loss widened to $1.7M from $1.6M as G&A jumped on $270K warrant comp to the CEO. Cash dwindled to $87K amid $777K ops burn; debt mix includes $1.1M convertible notes in default at 18% and $411K short-term convertibles. Debt conversions added $138K extinguishment hit. Stockholders' deficit sits at $5.6M. FDA trial data looks solid. Regulatory delays loom.
10-Q
Q2 FY2025 results
Guided Therapeutics posted Q2 revenue of $117K from device and disposable sales, up from nil a year ago but flat sequentially, with gross profit at $79K yielding a 67.5% margin. Operating loss widened to $763K y/y from $655K, driven by higher general and administrative costs including $270K in stock-based compensation, while R&D and sales expenses fell. Net loss hit $811K, or $0.01 per diluted share on 78.8M shares, matching last year but up q/q; the gap from operating loss stems from $157K interest expense. Cash dipped to $185K amid $500K operating burn, offset by $297K from financing including notes and a $205K private placement, leaving $6.4M total debt with key maturities in 2026 and revolver availability undisclosed. No M&A or impairments noted. Non-GAAP metrics not disclosed in the 10-Q. Competition in medical devices poses ongoing risks to market adoption.
10-Q
Q1 FY2025 results
Guided Therapeutics posted a Q1 net loss of $427K, up 6% y/y from $402K, driven by higher R&D costs for clinical trials while sales stayed negligible at zero. Operating expenses climbed 14% y/y to $414K, mainly from sponsored research, yet the company trimmed deferred revenue by $179K and recognized $180K in other income from a China partner agreement. Cash dwindled to $115K from $388K at year-end, with $331K used in operations offset by $205K from a private placement; total debt sits at $6M including $1.1M in defaulted convertible notes at 18% interest. No free cash flow disclosed in the 10-Q. Preferred dividends persist at $36K. Regulatory hurdles loom large.
CV
CapsoVision, Inc.
12.00-1.78
LUCD
Lucid Diagnostics Inc.
1.12+0.01
NVCR
NovoCure Limited
12.93-0.04
PAVM
PAVmed Inc.
0.31-0.01
PHG
Koninklijke Philips N.V. NY Reg
26.53+0.07
RDGL
Vivos Inc.
0.07-0.00
RPID
Rapid Micro Biosystems, Inc.
3.52+0.05
RXST
RxSight, Inc.
12.76+0.24
TOVX
Theriva Biologics, Inc.
0.21+0.01
VVOS
Vivos Therapeutics, Inc.
2.02+0.00